FierceBiotech

AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
FierceBiotech

AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
Precision Medicine Online

AstraZeneca Emphasizes Growth Potential From ADC Pipeline, Approved Cancer Drugs at JPM

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
Morningstar

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery

LONDON, UK and BUDAPEST, HUNGARY, Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca ...
Pharmabiz

AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension

AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...